Baxter International Inc.  

(Public, NYSE:BAX)   Watch this stock  
Find more results for BAX
67.24
-0.94 (-1.38%)
Oct 17 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 66.37 - 68.75
52 week 64.78 - 77.31
Open 68.35
Vol / Avg. 6.50M/2.80M
Mkt cap 36.42B
P/E 18.93
Div/yield 0.52/3.09
EPS 3.55
Shares 541.67M
Beta 0.72
Inst. own 82%
Oct 16, 2014
Q3 2014 Baxter International Inc Earnings Release
Oct 16, 2014
Q3 2014 Baxter International Inc Earnings Call - Webcast
Sep 24, 2014
Merrimack Pharmaceuticals Inc Conference Call to Discuss its Agreement with Baxter International Inc to Develop and Commercialize Novel Cancer Compound
Sep 8, 2014
Baxter International Inc at Morgan Stanley Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 12.20% 13.19%
Operating margin 16.79% 17.30%
EBITD margin - 35.66%
Return on average assets 8.20% 8.70%
Return on average equity 24.07% 26.13%
Employees 61,000 -
CDP Score - 82 B

Address

ONE BAXTER PKWY
DEERFIELD, IL 60015
United States - Map
+1-847-9482000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Baxter International Inc. (Baxter) is a global, diversified healthcare company. Baxter, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company operated in two segments: BioScience and Medication Delivery. It is engaged in the medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors� offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures products in 27 countries and sells the products in more than 100 countries. In September 2013, Baxter International Inc completed the acquisition of Gambro AB. Effective July 9, 2014, Baxter International Inc acquired AesRX LLC.

Officers and directors

Robert L. Parkinson Jr. Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Robert J. Hombach CPA Chief Financial Officer, Corporate Vice President
Age: 48
Bio & Compensation  - Reuters
David P. Scharf Corporate Vice President, General Counsel
Age: 46
Bio & Compensation  - Reuters
Sebastian J. Bufalino Corporate Vice President, Controller
Age: 53
Bio & Compensation  - Reuters
Todd S. Young Corporate Vice President, Treasurer
Bio & Compensation  - Reuters
Jeanne K. Mason Ph.D. Corporate Vice President - Human Resources
Age: 58
Bio & Compensation  - Reuters
Phillip L. Batchelor Corporate Vice President - Quality and Regulatory Affairs
Age: 52
Bio & Compensation  - Reuters
Jean-Luc Butel Corporate Vice President, President - International
Age: 57
Bio & Compensation  - Reuters
Ludwig N. Hantson Ph.D. Corporate Vice President, President - BioScience
Age: 51
Bio & Compensation  - Reuters
John Orloff M.D. Vice President, Global Head of Research and Development for Baxter BioScience
Bio & Compensation  - Reuters